GH action associates with reduced overall survival in multiple cancers, including bladder cancer [14], pancreatic [10], breast cancer [66,67], liver cancer [68], colorectal cancer [69], gastric cancer [70], and others [56]. This evidence concerns the gene GH1 and colorectal cancer.